Neptune Technology and Bioressources Inc. (Neptune; Laval, QC), a supplier of krill oil for dietary supplements, has introduced Onemia, a medical food for the pharmaceutical market.
Neptune Technology and Bioressources Inc. (Neptune; Laval, QC), a supplier of krill oil for dietary supplements, has introduced Onemia, a medical food for the pharmaceutical market.
Onemia is a marine-based omega-3 phospholipid deemed by FDA as safe and effective for managing chronic cardiometabolic disorders. Available through prescription, the product can be used alone or in combination with other cardiovascular drugs.
"The success of Onemia will provide short-term revenues which will contribute to Acasti's further research and development projects while establishing a validation of Acasti's omega-3 phospholipid pipeline…paving the road for CaPre, our prescription drug candidate in development," said Tina Sampalis, MD, PhD, president of Neptune.
Onemia is manufactured by Neptune and sold through the company’s subsidiary, Acasti Pharma Inc.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.